New Clinical Data to Showcase Atraverse Medical's HOTWIRE™ Guidewire Effectiveness at AF Symposium
Atraverse Medical is set to present substantial clinical evidence supporting the safety and effectiveness of its innovative HOTWIRE™ radiofrequency guidewire system during the upcoming 30th Annual International AF Symposium scheduled from January 16-18, 2025. This cutting-edge technology, designed to facilitate left-heart access, has already garnered attention with impressive results from over 130 successful transseptal procedures since receiving FDA clearance roughly eight months ago.
The HOTWIRE™ guidewire system represents a significant leap forward in procedural efficiency, tailored to streamline workflows while remaining agnostic to various therapies. Atraverse Medical, headquartered in San Diego, has developed this technology with the intention of addressing the growing demand for more effective and versatile solutions in the cardiology field. The company plans to showcase the HOTWIRE™ at Booth No. 111 throughout the symposium, offering attendees a firsthand look at this groundbreaking advancement.
During the symposium, Atraverse will also unveil two late-breaking posters that detail both preclinical research and the initial clinical experiences surrounding the HOTWIRE™. The first poster, authored by Dr. Devi Nair, presents a multicenter experience using this novel radiofrequency transseptal wire. The second, led by Dr. Jeremiah Wasserlauf, discusses how impedance-based energy cessation can effectively reduce energy duration during RF-powered transseptal puncture. Dr. Devi Nair, a prominent figure in cardiac electrophysiology and the first clinician to utilize the HOTWIRE™ in practice, shared his thoughts, stating that it is exciting to witness the translation of pre-clinical results into clinical practice. His early experiences with the HOTWIRE™ reflect a promising safety profile and highlight its capability to enhance workflow efficiency.
Eric Sauter, the Chief Operating Officer and co-founder of Atraverse Medical, emphasized the extensive research and rigorous biomedical studies that have gone into developing the HOTWIRE™ system for ensuring a safe and user-friendly product. These recent findings underscore the company's commitment to innovation and respond to the pressing need for improved technologies in this medical sector. Since its FDA clearance in May 2024, the HOTWIRE™ device has not only demonstrated its efficiency but has also improved patient outcomes by providing zero exchange left-heart access, allowing it to serve as a reliable rail for catheter-based therapy systems. With universal sheath compatibility, this guidewire truly represents a pivotal advancement in access technology and procedural workflows.
Founded in July 2022 by Dr. Steven Mickelson, John Slump, and Eric Sauter, Atraverse Medical aims to redefine left-heart access and optimize radiofrequency technology. Drawing from the experience of its founders, who previously established FARAPULSE, the company is committed to enhancing the treatment of cardiovascular diseases impacting millions of patients worldwide. For more details about these innovative products or their impact on medical practices, visit their website at www.atraversemedical.com.
As the AF Symposium approaches, attendees can anticipate critical insights into the future of left-heart access as Atraverse Medical continues to validate the role of its HOTWIRE™ system in leading-edge cardiovascular procedures.
The HOTWIRE™ guidewire system represents a significant leap forward in procedural efficiency, tailored to streamline workflows while remaining agnostic to various therapies. Atraverse Medical, headquartered in San Diego, has developed this technology with the intention of addressing the growing demand for more effective and versatile solutions in the cardiology field. The company plans to showcase the HOTWIRE™ at Booth No. 111 throughout the symposium, offering attendees a firsthand look at this groundbreaking advancement.
During the symposium, Atraverse will also unveil two late-breaking posters that detail both preclinical research and the initial clinical experiences surrounding the HOTWIRE™. The first poster, authored by Dr. Devi Nair, presents a multicenter experience using this novel radiofrequency transseptal wire. The second, led by Dr. Jeremiah Wasserlauf, discusses how impedance-based energy cessation can effectively reduce energy duration during RF-powered transseptal puncture. Dr. Devi Nair, a prominent figure in cardiac electrophysiology and the first clinician to utilize the HOTWIRE™ in practice, shared his thoughts, stating that it is exciting to witness the translation of pre-clinical results into clinical practice. His early experiences with the HOTWIRE™ reflect a promising safety profile and highlight its capability to enhance workflow efficiency.
Eric Sauter, the Chief Operating Officer and co-founder of Atraverse Medical, emphasized the extensive research and rigorous biomedical studies that have gone into developing the HOTWIRE™ system for ensuring a safe and user-friendly product. These recent findings underscore the company's commitment to innovation and respond to the pressing need for improved technologies in this medical sector. Since its FDA clearance in May 2024, the HOTWIRE™ device has not only demonstrated its efficiency but has also improved patient outcomes by providing zero exchange left-heart access, allowing it to serve as a reliable rail for catheter-based therapy systems. With universal sheath compatibility, this guidewire truly represents a pivotal advancement in access technology and procedural workflows.
Founded in July 2022 by Dr. Steven Mickelson, John Slump, and Eric Sauter, Atraverse Medical aims to redefine left-heart access and optimize radiofrequency technology. Drawing from the experience of its founders, who previously established FARAPULSE, the company is committed to enhancing the treatment of cardiovascular diseases impacting millions of patients worldwide. For more details about these innovative products or their impact on medical practices, visit their website at www.atraversemedical.com.
As the AF Symposium approaches, attendees can anticipate critical insights into the future of left-heart access as Atraverse Medical continues to validate the role of its HOTWIRE™ system in leading-edge cardiovascular procedures.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.